Treatment.com AI inc. Announces Debt Settlement Transactions

Vancouver, British Columbia, March 21, 2024 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) announces that it proposes to enter into debt settlement agreements with certain arms’ length creditors (the “Creditors”) to settle an aggregate of CAD$461,307.40 in debt (the “Debt”). The Debt relates to outstanding principal and accrued interest on the Company’s 8% unsecured convertible debentures issued on May 17, 2022.  In settlement of the Debt, the Company will issue an aggregate of 1,153,266 units of the Company (the “Units”) at a deemed price of $0.40 per Unit (the “Debt Settlement”), with each Unit to be comprised of one common share in the capital of the Company (a “Share”) and one-half of one Share purchase warrant (each whole warrant a “Warrant”). Each whole Warrant will entitle the holder thereof to purchase one additional Share (a “Warrant Share”) at a price of $0.60 per Warrant Share for a period of 24 months from the date of issuance.

All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

The securities issued pursuant to the Debt Settlement have will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.


Dr. Essam Hamza, CEO ehamza@treatment.com 1 (612) 788-8900

Toll Free:

1 (888) 788-8955

Cautionary Statement

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy of accuracy of this news release.

This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Debt Settlement, the entering into and consummation of the debt settlement agreements with the Creditors, and the Closing of the Debt Settlement are forward- looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.